How Much Does Medical Device Cybersecurity Cost in 2026?

The cost question almost never arrives in a vacuum. It arrives attached to a board asking why this line item exists, a launch budget that has to absorb it, or a regulatory lead who just got an FDA AI letter and needs a number by Friday. The answer most firms give - "it depends, contact us" - is correct but useless, and it loses the buyer who is trying to do the job seriously.

This piece does the opposite. It walks through what actually moves the price, why fixed-fee pricing protects you from re-test surprises, how to budget premarket and postmarket separately, and how to weigh the engagement fee against the only number that really matters: the revenue lost to a delayed clearance.

Key Takeaways

• Medical device cybersecurity cost is set by four drivers: device complexity, submission pathway (510(k) / De Novo / PMA), attack surface, and premarket-only vs premarket-plus-postmarket scope.
• Fixed-fee engagements with unlimited retesting remove re-test surprises and scope-creep risk; hourly FDA cybersecurity consulting fees push that risk onto the buyer.
• Premarket cybersecurity is a finite project tied to the submission; postmarket is a recurring annual obligation under Section 524B and belongs on a separate budget line.
• Retrofitting cybersecurity after design lock is the single most expensive scenario - it triggers re-validation, a fresh threat model, and often a new submission cycle.
• A three-month clearance delay on a $40M-revenue device routinely costs more than 10x a complete fixed-fee cybersecurity engagement.

Table of Contents

• What Drives the Cost of Medical Device Cybersecurity?
• Fixed-Fee vs Hourly: How Cybersecurity Consulting Is Priced
• Premarket vs Postmarket: Two Different Budget Lines
• The Cost of Delay: What Skipping or Under-Scoping Really Costs
• How to Build a Realistic Cybersecurity Budget
• How Blue Goat Cyber Prices Engagements
• Frequently Asked Questions

Why This Matters

Under Section 524B of the FD&C Act and the FDA's final guidance "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions," issued February 3, 2026, every cyber device submission must include a defined cybersecurity evidence package - threat model, SBOM, secure architecture views, independent testing, postmarket plan. The FDA can issue a Refuse-to-Accept inside the 15-day RTA window if any of those artifacts are missing or thin, which means budgeting cybersecurity as an afterthought is functionally equivalent to budgeting a launch delay.

The delay is the real cost. Independent reporting from MedTech Dive and others on recent device recalls (Medtronic, BD, Philips) has shown cybersecurity-driven holds routinely pushing clearance by 3-9 months. For a connected device projecting $30-50M in first-year revenue, a single quarter of delay outweighs the entire engagement fee by an order of magnitude.

The applicable standards stack - AAMI SW96 (FDA-recognized as 13-122), AAMI TIR57, IEC 81001-5-1, IEC 62304, ISO 14971, and the IMDRF Principles and Practices for Medical Device Cybersecurity - all assume the work is built in during design, not retrofitted after MVP. Pricing follows the same logic: scoped early, the work is cheap and predictable. Scoped late, every dollar buys less.

What Drives the Cost of Medical Device Cybersecurity?

The cost of a cybersecurity engagement is set by your device, not by the consultant. Four factors do most of the work, and once you can describe them, any competent firm can give you a real number.

• Device complexity. A standalone, single-purpose Class II device with one wireless interface costs a fraction of a connected, multi-component system that pairs an implant, a clinician programmer, a patient remote, and a cloud back end.
• Submission pathway. 510(k) usually carries the lightest cyber documentation burden. De Novo and PMA expect more depth in the threat model, more independent test evidence, and tighter postmarket commitments.
• Attack surface to be tested. Each interface - firmware, BLE or proprietary RF, mobile app, cloud APIs, third-party integrations - is its own test scope. The number of interfaces, not the number of features, is what determines pen-test effort.
• Premarket only, postmarket only, or both. Premarket is a defined project tied to your submission. Postmarket is an ongoing annual obligation under Section 524B. Treat them as separate budget lines (more on this below).

A useful way to sense-check a quote: if a firm cannot tell you which of these four factors drove the number up, the number is a guess.

Cost drivers at a glance

Cost driver	Lower cost → Higher cost
Submission pathway	510(k) → De Novo → PMA
Device connectivity	Standalone → Wireless / cloud-connected
Attack surface	Single interface → Firmware + BLE/RF + mobile + cloud + APIs
Software origin	First-party only → Heavy third-party / open-source (SBOM depth)
Engagement scope	Premarket only → Premarket + ongoing postmarket
Starting point	Security designed in → Retrofitting after design lock

Fixed-Fee vs Hourly: How Cybersecurity Consulting Is Priced

There are two honest pricing models in this market, and they create very different buyer experiences.

Hourly FDA cybersecurity consulting fees are common with generalist security firms and adjacent regulatory consultancies. The hourly rate looks predictable, but the total is not. Threat models expand as the architecture clarifies, pen tests spawn re-tests after every fix, and deficiency responses turn into new scopes of work. The buyer carries every minute of scope drift.

Fixed-fee engagements with unlimited retesting flip that risk. The firm commits to a number for a defined deliverable - threat model, SBOM, pen test, submission package - and absorbs the cost of additional test passes until the device reaches acceptable risk. You know what you are paying on day one, and the firm is incentivized to get the architecture right early instead of billing for the re-work.

For a regulated, safety-critical product on a launch deadline, fixed-fee with unlimited retesting is the model that protects the buyer. It is also the model FDA reviewers indirectly reward, because firms that price this way cannot afford to ship sloppy evidence.

Premarket vs Postmarket: Two Different Budget Lines

One of the most expensive budgeting mistakes is treating cybersecurity as a single one-time line on the launch budget. It is two lines, and they behave differently.

Premarket is a defined project tied to your submission. Threat model, SBOM, security architecture views, pen test, labeling, the SPDF documentation - all of it lands in the submission package, gets reviewed once, and gets cleared. The cost is finite and forecastable.

Postmarket is an ongoing annual obligation under Section 524B. SBOM monitoring, vulnerability disclosure, periodic reporting, coordinated response to new CVEs, and software updates have to keep happening for the life of the device. That is not a project - it is a recurring operational line, and finance should plan for it the same way they plan for cloud hosting or compliance audits.

Firms that try to sell postmarket as a one-time deliverable are either misunderstanding 524B or hoping you do. Our FDA Postmarket Cybersecurity Services page lays out what the annual program actually includes and how it is scoped.

The Cost of Delay: What Skipping or Under-Scoping Really Costs

See also: FDA Section 524B Explained Subsection by Subsection: What Each Requirement Means in 2026, Guide to Medical Device Cybersecurity Standards, and CAPA and Medical Device Cybersecurity: Closing the Loop on Vulnerabilities and FDA Deficiencies.

The cost of cybersecurity work is small. The cost of a delayed clearance is not.

A connected MedTech device with $40M in projected first-year revenue is generating roughly $110K per day from the moment it ships. A three-month delay caused by a cybersecurity deficiency - a missing SBOM, an unsigned firmware update path, an unmodeled threat in a wireless interface - costs about $10M in deferred revenue, plus the burn rate of an engineering team waiting for a fix.

The cybersecurity engagement that would have prevented that deficiency is almost always a small fraction of that number. That is the math that matters, and it is the math FDA reviewers implicitly assume you have already done.

Plug your own numbers into the Cost-of-Delay calculator before you finalize your cybersecurity budget. If the model says delay is cheaper than diligence, you have a different problem than pricing.

How to Build a Realistic Cybersecurity Budget

A realistic budget is built in four steps, in this order:

1. Scope the attack surface early - before design lock. Every interface you add after design lock is more expensive to secure than the same interface added during architecture. Get a threat model on the table while changes are still cheap.
2. Decide premarket vs postmarket scope explicitly. Some buyers only need premarket because they already have a postmarket program. Most growth-stage MedTech companies need both. Decide deliberately.
3. Use a Scope Estimator to get a starting range. The Scope Estimator takes the same four drivers above - complexity, pathway, attack surface, premarket/postmarket - and returns a fixed-fee range you can actually budget against, without a sales call.
4. Refine with a strategy call. A 30-minute call closes the gap between the estimator's range and the final fixed-fee quote, by walking the architecture and the submission timeline together.

Doing this before design lock is the single highest-ROI move in the whole budget cycle.

Want a fixed-fee number for your device? Use the Scope Estimator for a self-serve range, or book a strategy call to refine it against your architecture and timeline.

How Blue Goat Cyber Prices Engagements

Every Blue Goat Cyber engagement is fixed-fee with unlimited retesting. That means one number for the scope, and as many test passes as it takes to reach acceptable risk - not an hourly meter, not a re-test surcharge, not a scope-change argument three weeks before submission.

Cost certainty extends past clearance: if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost to you. That guarantee only works because we ship the same evidence pattern reviewers expect - AAMI SW96-aligned risk file, traceable threat model, signed-update architecture, independent pen test, postmarket plan - and because the team has carried hundreds of devices through 510(k), De Novo, and PMA pathways.

The mechanics are simple. You describe the device. We scope the four drivers. You receive a fixed-fee proposal with the deliverables, the timeline, and the retesting commitment in writing. Most engagements ship to the FDA on a known calendar date.

For the full premarket scope and methodology, see FDA Premarket Cybersecurity Services.

Frequently asked questions

How much does medical device cybersecurity cost?

Cost depends on device complexity, submission pathway, attack surface, and whether you need premarket work, postmarket support, or both. Specialist firms typically price fixed-fee with unlimited retesting, so the figure is known up front. Use a scope estimator for a device-specific range, and weigh it against the revenue lost to a single delayed launch - that is the comparison that determines whether the spend is justified.

Is medical device cybersecurity priced hourly or fixed-fee?

Both models exist. Hourly FDA cybersecurity consulting fees can drift as scope grows and re-tests add up - the buyer carries the risk of every extra pass. Fixed-fee engagements with unlimited retesting give a known total and remove the re-test surprise; the firm absorbs the cost of getting the device to acceptable risk, no matter how many passes it takes.

What's the difference between premarket and postmarket cybersecurity cost?

Premarket is a defined project tied to your submission - threat model, SBOM, pen test, submission package, cleared once. Postmarket is an ongoing annual obligation under Section 524B - SBOM monitoring, vulnerability disclosure, periodic reporting - so it is a recurring budget line, not a one-time fee. Budget for both if your device is heading to market and staying there.

How do I budget for medical device cybersecurity?

Scope the attack surface early - before design lock, when changes are still cheap - then decide premarket vs postmarket scope and get a fixed-fee quote. A scope estimator gives a starting range; a strategy call refines it. Building the medical device security budget early avoids the most expensive cost: retrofitting security after design lock, which triggers re-validation, a fresh threat model, and often a new submission cycle.

Isn't it cheaper to skip cybersecurity until FDA asks?

No - it is the most expensive path. Under Section 524B, the FDA can refuse to accept a submission missing required cybersecurity information, and retrofitting evidence after design lock costs more than building it in. A delay measured in months usually dwarfs the engagement fee in lost revenue. Run your own numbers through the Cost-of-Delay calculator before you defer the work.

Get a fixed-fee number for your device

Stop estimating. Use the Scope Estimator to get a fixed-fee range in minutes, or book a strategy call and we will scope your device, your pathway, and your timeline against a written guarantee - no hourly meter, no re-test surcharge, no surprises at submission.

---

About the author. Christian Espinosa, MBA, CISSP - Founder & CEO, Blue Goat Cyber. Christian has scoped and priced hundreds of FDA cybersecurity engagements across 510(k), De Novo, and PMA pathways, and built the fixed-fee + unlimited-retesting model the firm runs on today. More from Christian.